Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$10.9MCash on Hand
3.1mo Cash Runway
Follow IPHA by emailGet an email when IPHA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about IPHA, unsubscribe in one click. Privacy
📣 What IPHA Says Is Next
first half of 2027 · “As announced on October 27 ( Link PR ) , AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously.”
Company press release, Nov 5, 2026 · SEC filing
Q1 2027 · Lacutamab: “Following closing of the transaction, Innate is advancing TELLOMAK-3, the confirmatory Phase 3 study of lacutamab in Cutaneous T Cell Lymphoma (CTCL), with first patient dosing expected in Q1 2027.”
Company press release, Nov 5, 2026 · SEC filing
first half of 2027 · Monalizumab: “We also look forward to the readout of the AstraZeneca-led PACIFIC-9 Phase 3 trial, which includes monalizumab and is now expected in the first half of 2027.” 1 Including short term investments (€20.6m) and non-current financial instruments (€6.0m).”
Company press release, Nov 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Innate Pharma will host an in-person and virtual event on November 18, 2026 in London to discuss Phase 1 data for its Nectin-4 ADC IPH4502, presented at the 2026 EORTC-NCI-AACR Symposium, with a live Q&A session. Form 6-K · SEC filing · Press release
Nov 5, 2026 ·
Leadership Reported Q3 2026 update: cash, equivalents and financial assets of €96.8 million at September 30, 2026, with cash runway until end of Q1 2028. Nine-month revenue was €3.4 million. CFO Frédéric Lombard steps down December 31, 2026. Phase 1 IPH4502 data due November 18. Form 6-K · SEC filing · Press release
Oct 27, 2026 ·
Clinical trial Innate Pharma said AstraZeneca has moved the expected high-level data readout for the PACIFIC-9 Phase 3 trial of durvalumab with monalizumab or oleclumab in unresectable Stage III NSCLC to the first half of 2027, from the second half of 2026. Form 6-K · SEC filing · Press release
Oct 21, 2026 ·
Innate Pharma will have executives present at the Stifel Healthcare Conference in New York on November 10 to 12, 2026, with a fireside chat on November 10 at 2:00 p.m. ET, and at the Jefferies Global Healthcare Conference in London on November 16 to 19, 2026. Form 6-K · SEC filing · Press release
Oct 20, 2026 ·
Innate Pharma will hold a conference call on November 5, 2026, at 2:00 p.m. CET / 8:00 a.m. ET to provide a business and financial update for the third quarter of 2026. Form 6-K · SEC filing · Press release
Sep 17, 2026 ·
Deal Innate Pharma said its partnership with Sobi for lacutamab is now effective after antitrust waiting periods and other conditions were met. Closing triggers a USD 75 million upfront payment and starts the TELLOMAK-3 Phase 3 study, with first patient expected in Q1 2027. Form 6-K · SEC filing · Press release
Sep 17, 2026 ·
Earnings Innate Pharma's half-year report for the period ended June 30, 2026, was approved by the Board on September 16, 2026, with a limited review by Statutory Auditors. The filing also notes a strategic partnership with Swedish Orphan Biovitrum AB dated August 10, 2026, and a capital increase on August 18, 2026. Form 6-K · SEC filing · Press release
Sep 17, 2026 ·
Earnings Reported H1 2026 results with €21.4 million cash as of June 30, 2026, runway to end of Q1 2028 including Sobi's $75 million upfront payment for lacutamab and proceeds from a €30 million capital increase. TELLOMAK-3 Phase 3 first patient expected Q1 2027. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Nov 2026 · N/A · Recruiting · Evaluation of the Performance and Safety of a Single-dose Hyaluronic Acid (Promovia Hydro Balance) in the Treatment of Non-traumatic Degenerative Meniscus Tears Registry primary completion date, not a results date
Jun 2027 · Phase 2 · Recruiting · IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) Registry primary completion date, not a results date
Apr 2028 · Phase 1 · Active Trial · Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors Registry primary completion date, not a results date
May 2026 · N/A · Active Trial · Clinical Investigation to Assess Safety and Efficacy of INNEA AQUA in Adult Women With Vulvo-Vaginal Atrophy (VVA) Registry date passed, readout not confirmed
Also used in these trials (approved or third-party drugs, not IPHA's own candidates): Cetuximab, Oxaliplatin, Gemcitabine Hydrochloride.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
IPHA holds $10.9M in cash and short-term investments and burns about $10.7M/quarter from operations,
an estimated runway of 3.1 months at that rate (BioRadar estimate, not company guidance).
Share count 93,719,323 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full IPHA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IPHA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.